The invention provides a cyclopropanecarboxamide derivative G
crystal form (please see the specification for the formula) in the formula (I). According to the XRPD illustration of the
crystal form,
diffraction peaks exist when 2Q is equal to 8.376, 9.76, 10.5, 12.402, 13.362, 14.081, 14.958, 17.16, 17.758, 19.358, 21.579, 22.34, 22.981, 23.241, 24.459, 24.919, 25.443, 26.7, 27.419, 27.818, 28.378, 29.461, 31.001, 33.56, 34.5 and 35.58, and the error range of the 2Q value is + / -0.2. The cyclopropanecarboxamide derivative G
crystal form has good high-temperature stability, high-
humidity stability and illumination stability. Moreover, excellent
solubility is achieved. The cyclopropanecarboxamide derivative G crystal form can be applied to drugs for treatment or prevention of JAK-participated
inflammation and
autoimmunity diseases, proliferative diseases, graft rejective reactions and congenital
cartilage deformation or diseases caused by IL6 oversecretion, and good
bioavailability is further achieved. Meanwhile, qualitative and quantitative information is provided, which is of important significance to further studying the
curative effect of the
solid drugs.